| Tumor necrosis factor α blockade: an opportunity to tackle breast cancer MF Mercogliano, S Bruni, PV Elizalde, R Schillaci Frontiers in oncology 10, 584, 2020 | 149 | 2020 |
| TNFα-induced mucin 4 expression elicits trastuzumab resistance in HER2-positive breast cancer MF Mercogliano, M De Martino, L Venturutti, MA Rivas, CJ Proietti, ... Clinical Cancer Research 23 (3), 636-648, 2017 | 109 | 2017 |
| p42/p44 MAPK-mediated Stat3 Ser727 phosphorylation is required for progestin-induced full activation of Stat3 and breast cancer growth M Tkach, C Rosemblit, MA Rivas, CJ Proietti Anastasi, MC Díaz Flaqué, ... Bioscientifica, 2013 | 98 | 2013 |
| MiR-16 mediates trastuzumab and lapatinib response in ErbB-2-positive breast and gastric cancer via its novel targets CCNJ and FUBP1 L Venturutti, RI Cordo Russo, MA Rivas, MF Mercogliano, F Izzo, ... Oncogene 35 (48), 6189-6202, 2016 | 86 | 2016 |
| Stat3 regulates ErbB-2 expression and co-opts ErbB-2 nuclear function to induce miR-21 expression, PDCD4 downregulation and breast cancer metastasis L Venturutti, LV Romero, AJ Urtreger, MF Chervo, RI Cordo Russo, ... Oncogene 35 (17), 2208-2222, 2016 | 75 | 2016 |
| Harnessing tumor necrosis factor alpha to achieve effective cancer immunotherapy MF Mercogliano, S Bruni, F Mauro, PV Elizalde, R Schillaci Cancers 13 (3), 564, 2021 | 68 | 2021 |
| Juvenile exposure to a high fat diet promotes behavioral and limbic alterations in the absence of obesity A Vinuesa, C Pomilio, M Menafra, MM Bonaventura, L Garay, ... Psychoneuroendocrinology 72, 22-33, 2016 | 65 | 2016 |
| Progesterone receptor assembly of a transcriptional complex along with activator protein 1, signal transducer and activator of transcription 3 and ErbB-2 governs breast cancer … MC Diaz Flaque, NM Galigniana, W Béguelin, R Vicario, CJ Proietti, ... Breast Cancer Research 15, 1-24, 2013 | 46 | 2013 |
| Progesterone receptor activation downregulates GATA3 by transcriptional repression and increased protein turnover promoting breast tumor growth F Izzo, F Mercogliano, L Venturutti, M Tkach, G Inurrigarro, R Schillaci, ... Breast Cancer Research 16, 1-17, 2014 | 38 | 2014 |
| Emerging targeted therapies for HER2-positive breast cancer MF Mercogliano, S Bruni, FL Mauro, R Schillaci Cancers 15 (7), 1987, 2023 | 36 | 2023 |
| Progesterone-induced stimulation of mammary tumorigenesis is due to the progesterone metabolite, 5α-dihydroprogesterone (5αP) and can be suppressed by the 5α-reductase … JP Wiebe, MA Rivas, MF Mercogliano, PV Elizalde, R Schillaci The Journal of steroid biochemistry and molecular biology 149, 27-34, 2015 | 29 | 2015 |
| Invasive micropapillary carcinoma of the breast overexpresses MUC4 and is associated with poor outcome to adjuvant trastuzumab in HER2-positive breast cancer MF Mercogliano, G Inurrigarro, M De Martino, L Venturutti, MA Rivas, ... BMC cancer 17, 1-8, 2017 | 24 | 2017 |
| Inhibition of MHC‐I by Brucella abortus is an early event during infection and involves EGFR pathway LN Velásquez, MA Milillo, MV Delpino, A Trotta, MF Mercogliano, ... Immunology and Cell Biology 95 (4), 388-398, 2017 | 21 | 2017 |
| Blockade of Stat3 oncogene addiction induces cellular senescence and reveals a cell-nonautonomous activity suitable for cancer immunotherapy M De Martino, M Tkach, S Bruni, D Rocha, MF Mercogliano, ... Oncoimmunology 9 (1), 1715767, 2020 | 19 | 2020 |
| FXYD5/Dysadherin, a biomarker of endometrial cancer myometrial invasion and aggressiveness: its relationship with TGF-β1 and NF-κB pathways MJ Besso, M Rosso, L Lapyckyj, CP Moiola, ML Matos, MF Mercogliano, ... Frontiers in Oncology 9, 1306, 2019 | 16 | 2019 |
| Comprehensive identification of pathogenic gene variants in patients with neuroendocrine disorders SA Vishnopolska, MF Mercogliano, MA Camilletti, AH Mortensen, ... The Journal of Clinical Endocrinology & Metabolism 106 (7), 1956-1976, 2021 | 15 | 2021 |
| Heregulin co-opts PR transcriptional action via Stat3 role as a coregulator to drive cancer growth CJ Proietti, F Izzo, MC Díaz Flaqué, R Cordo Russo, L Venturutti, ... Molecular Endocrinology 29 (10), 1468-1485, 2015 | 13 | 2015 |
| Blocking soluble TNFα sensitizes HER2-positive breast cancer to trastuzumab through MUC4 downregulation and subverts immunosuppression S Bruni, FL Mauro, CJ Proietti, RI Cordo-Russo, MA Rivas, G Inurrigarro, ... Journal for Immunotherapy of Cancer 11 (3), 2023 | 10 | 2023 |
| Halting ErbB-2 isoforms retrograde transport to the nucleus as a new theragnostic approach for triple-negative breast cancer S Madera, F Izzo, MF Chervo, A Dupont, VA Chiauzzi, S Bruni, E Petrillo, ... Cell Death & Disease 13 (5), 447, 2022 | 9 | 2022 |
| Tumor necrosis factor α blockade: an opportunity to tackle breast cancer. Front Oncol 10: 584 MF Mercogliano, S Bruni, PV Elizalde, R Schillaci | 9 | 2020 |
